PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35061107-0	2022	Modulating Expression of Endogenous Interleukin 1 Beta in the Acute Phase of the Pilocarpine Model of Epilepsy May Change Animal Survival.	Pilocarpine	81-92	interleukin 1 beta	Homo sapiens	36-54	
35061107-7	2022	We found that knocking down Il1b prior to pilocarpine injection increased the mortality rate of treated animals.	Pilocarpine	42-53	interleukin 1 beta	Homo sapiens	28-32	
35061107-8	2022	Furthermore, we observed that, when exposing the animals to more Il1b by silencing its endogenous antagonist Il1rn, there was a better response to status epilepticus with decreased animal mortality in the acute phase of the PILO model.	Pilocarpine hydrochloride	224-228	interleukin 1 beta	Homo sapiens	65-69	
35061107-8	2022	Furthermore, we observed that, when exposing the animals to more Il1b by silencing its endogenous antagonist Il1rn, there was a better response to status epilepticus with decreased animal mortality in the acute phase of the PILO model.	Pilocarpine hydrochloride	224-228	interleukin 1 receptor antagonist	Homo sapiens	109-114	
35061107-10	2022	Furthermore, our results provide suggestive evidence that modulating endogenous Il1b improves animal survival in the acute phase of the PILO model and may have effects that extend into the chronic phase.	Pilocarpine hydrochloride	136-140	interleukin 1 beta	Homo sapiens	80-84